Article Figures & Data
Tables
Presence of Damage and/or Disability No Damage, No Disability, No Mild/moderate Psoriasis Damage and/or Disability and Multiple Failed bDMARD Subtype Peripheral Axial Peripheral Axial Primary bDMARD continuation criteria DAPSA ≤ 14 and ΔPsAID ≤ (−3) ASDAS ≤ 2.1 and ΔPsAID ≤ (−3) DAPSA ≤ 14 ASDAS ≤ 2.1 Primary T2T goal DAPSA ≤ 4 MDA ASDAS ≤ 1.3 DAPSA ≤ 4 MDA ASDAS ≤ 1.3 Alternative bDMARD continuation criteria DAPSA ≤ 4* ASDAS ≤ 1.3* ΔDAPSA ≤ (−85%) and PsAID ≤ 4 ΔASDAS ≤ (−1.1) and PsAID ≤ 4 Alternative T2T goal DAPSA ≤ 14 ASDAS ≤ 2.1 DAPSA ≤ 14 ASDAS ≤ 2.1 ↵* Alternative target allowed in this category if there is 1 bDMARD failure. bDMARD: biological disease-modifying antirheumatic drugs; DAPSA: Disease Activity in Psoriatic Arthritis; PsAID: Psoriatic Arthritis Impact of Disease; ASDAS: Ankylosing Spondylitis Disease Activity Score; T2T: treat to target; MDA: moderate disease activity.
- Table 2.
Parallel between the psoriatic arthritis (PsA) core outcome set (COS) and the proposed effectiveness targets.
PsA COS Peripheral Axial DAPSA PsAID ASDAS Arthritis 68 tender/66 swollen joint counts — — Dactylitis — — — Enthesitis — — — Spondyloarthritis — — BASDAI – Duration morning stiffness Psoriasis — PsAID – Psoriasis — Nail psoriasis — — — Pain Pain VAS PsAID – Pain BASDAI – Spinal pain BASDAI – Peripheral pain Patient global Patient global assessment VAS — Patient global assessment Physical function — PsAID – Functional capacity — Fatigue — PsAID – Fatigue — Life effect/HRQOL PsAID total score Systemic inflammation CRP — CRP DAPSA: Disease Activity in Psoriatic Arthritis; PsAID: Psoriatic Arthritis Impact of Disease; ASDAS: Ankylosing Spondylitis Disease Activity Score; BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; VAS: visual analog scale; HRQOL: health-related quality of life; CRP: C-reactive protein.
